Senores Pharmaceuticals Limited has informed the Exchange regarding a corrigendum to the Media Release submitted with the Outcome of the Board Meeting dated May 14, 2026
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals has issued a corrigendum to correct a typing error in the Media Release accompanying its Board Meeting outcome. The corrigendum replaces the faulty Annexure B with a revised Media Release. The corrected filing shows strong FY26 performance with Total Income of Rs. 664 Crs (up 62% YoY), EBITDA of Rs. 200 Crs (up 96% YoY), and PAT of Rs. 122 Crs (up 108% YoY). Q4 FY26 also showed robust growth with Total Income of Rs. 190 Crs, EBITDA of Rs. 62 Crs, and PAT of Rs. 37 Crs. The company highlighted 51 approved ANDAs, recent acquisitions (Zoraya Pharmaceuticals, Apnar Pharmaceuticals), and a new joint venture Amerisyn for U.S. federal market access.
The corrigendum is a routine administrative correction addressing a typing error only and does not change any financial figures or business substance. The strong FY26 results remain valid and reflect significant growth across regulated markets, emerging markets, and branded generics segments.